{"id":2336,"date":"2020-07-10T00:00:00","date_gmt":"2020-07-10T00:00:00","guid":{"rendered":"http:\/\/centogene.vl22350.dinaserver.com\/2336"},"modified":"2020-07-10T00:00:00","modified_gmt":"2020-07-10T00:00:00","slug":"centogene-oglasza-ceny-pierwotnej-i-wtornej-oferty-publicznej-akcji-zwyklych","status":"publish","type":"post","link":"https:\/\/www.centogene.com\/pl\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/","title":{"rendered":"CENTOGENE og\u0142asza cen\u0119 pierwotnej i wt\u00f3rnej oferty publicznej akcji zwyk\u0142ych"},"content":{"rendered":"<p>CAMBRIDGE, Mass. i ROSTOCK, Niemcy i BERLIN, 9 lipca 2020 r. (Globe Newswire) \u2013 Centogene NV (Nasdaq: CNTG) (\u201cCentogene\u201d lub \u201cSp\u00f3\u0142ka\u201d), sp\u00f3\u0142ka komercyjna skupiaj\u0105ca si\u0119 na rzadkich chorobach, kt\u00f3ra przekszta\u0142ca rzeczywiste dane kliniczne i genetyczne w u\u017cyteczne informacje dla pacjent\u00f3w, lekarzy i firm farmaceutycznych, og\u0142osi\u0142a dzi\u015b cen\u0119 swojej pierwotnej i wt\u00f3rnej oferty publicznej 3 500 000 akcji zwyk\u0142ych Sp\u00f3\u0142ki, sk\u0142adaj\u0105cej si\u0119 z 2 000 000 akcji zwyk\u0142ych oferowanych przez Sp\u00f3\u0142k\u0119 i 1 500 000 akcji zwyk\u0142ych oferowanych przez akcjonariuszy sprzedaj\u0105cych po cenie publicznej $14,00 za akcj\u0119 zwyk\u0142\u0105, co daje Sp\u00f3\u0142ce ca\u0142kowity przych\u00f3d brutto w wysoko\u015bci $28 mln i ca\u0142kowity przych\u00f3d brutto dla akcjonariuszy sprzedaj\u0105cych w wysoko\u015bci $21 mln. Sp\u00f3\u0142ka nie otrzyma \u017cadnych wp\u0142yw\u00f3w ze sprzeda\u017cy akcji zwyk\u0142ych przez akcjonariuszy sprzedaj\u0105cych. Ponadto akcjonariusze sprzedaj\u0105cy przyznali gwarantom 30-dniow\u0105 opcj\u0119 zakupu do 525 000 dodatkowych akcji zwyk\u0142ych po cenie oferty publicznej, pomniejszonej o dyskonto i prowizje gwaranta emisji.<\/p>\n<p>Oczekuje si\u0119, \u017ce oferta zostanie zamkni\u0119ta oko\u0142o 14 lipca 2020 r., zgodnie ze zwyczajowymi warunkami zamkni\u0119cia.<\/p>\n<p>Credit Suisse i SVB Leerink pe\u0142ni\u0105 funkcj\u0119 wsp\u00f3\u0142mened\u017cer\u00f3w ksi\u0119gi popytu, a Baird, BTIG i Kempen &amp; Co s\u0105 wsp\u00f3\u0142mened\u017cerami.<\/p>\n<p>Centogene zamierza przeznaczy\u0107 doch\u00f3d netto z oferty na badania i rozw\u00f3j, wspieraj\u0105c rozw\u00f3j lek\u00f3w sierocych za pomoc\u0105 swojej platformy informacyjnej opartej na wiedzy, a tak\u017ce na kapita\u0142 obrotowy i inne og\u00f3lne cele korporacyjne. Cz\u0119\u015b\u0107 dochodu netto mo\u017ce r\u00f3wnie\u017c zosta\u0107 przeznaczona na nabycie lub inwestycje w komplementarne przedsi\u0119biorstwa, aktywa lub technologie.<\/p>\n<p>Komisja Papier\u00f3w Warto\u015bciowych i Gie\u0142d (\u201cSEC\u201d) og\u0142osi\u0142a 9 lipca 2020 r., \u017ce o\u015bwiadczenie rejestracyjne dotycz\u0105ce tych papier\u00f3w warto\u015bciowych jest skuteczne. Oferta jest dokonywana wy\u0142\u0105cznie za po\u015brednictwem prospektu emisyjnego. Egzemplarze ostatecznego prospektu emisyjnego dotycz\u0105cego oferty mo\u017cna uzyska\u0107 bezp\u0142atnie, odwiedzaj\u0105c stron\u0119 internetow\u0105 EDGAR pod adresem www.sec.gov. Alternatywnie, egzemplarze ostatecznego prospektu emisyjnego, gdy b\u0119d\u0105 dost\u0119pne, mo\u017cna uzyska\u0107 w Credit Suisse Securities (USA) LLC, z dopiskiem: Dzia\u0142 Prospekt\u00f3w, 6933 Louis Stephens Drive, Morrisville, NC 27560, telefonicznie pod numerem (800) 221-1037 lub e-mailem pod adresem usa.prospectus@credit-suisse.com; lub SVB Leerink LLC, z dopiskiem: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, telefonicznie pod numerem (800) 808-7525, wew. 6218 lub e-mailem na adres syndicate@svbleerink.com.<\/p>\n<p>Niniejszy komunikat prasowy nie stanowi oferty sprzeda\u017cy ani zach\u0119ty do z\u0142o\u017cenia oferty kupna tych papier\u00f3w warto\u015bciowych. Nie b\u0119dzie r\u00f3wnie\u017c mia\u0142a miejsca sprzeda\u017c tych papier\u00f3w warto\u015bciowych w \u017cadnym stanie ani jurysdykcji, w kt\u00f3rych taka oferta, zach\u0119ta lub sprzeda\u017c by\u0142aby niezgodna z prawem przed rejestracj\u0105 lub kwalifikacj\u0105 zgodnie z przepisami prawa papier\u00f3w warto\u015bciowych obowi\u0105zuj\u0105cymi w takim stanie lub jurysdykcji.<\/p>\n<p>\u201cW CENTOGENE jeste\u015bmy dumni z tego, \u017ce zapewniamy naszym pacjentom testy diagnostyczne, kt\u00f3rym mog\u0105 zaufa\u0107\u201d \u2013 dodaje dr Florian Vogel, starszy wiceprezes ds. operacji laboratoryjnych. \u201cDzi\u0119ki naszej niedawnej inicjatywie testowania na COVID-19 udowodnili\u015bmy, \u017ce nawet w warunkach niedoboru zasob\u00f3w mo\u017cliwe jest szybkie opracowanie i dostarczenie wysokiej jako\u015bci test\u00f3w zgodnie z wytycznymi WHO\/CDC.<\/p>\n<h2 class=\"h3\">O firmie CENTOGENE<strong> <\/strong><\/h2>\n<p>CENTOGENE zajmuje si\u0119 diagnostyk\u0105 i badaniami nad chorobami rzadkimi, przekszta\u0142caj\u0105c rzeczywiste dane kliniczne i genetyczne w praktyczne informacje dla pacjent\u00f3w, lekarzy i firm farmaceutycznych. Naszym celem jest racjonalizacja decyzji terapeutycznych i przyspieszenie rozwoju nowych lek\u00f3w sierocych, wykorzystuj\u0105c nasz\u0105 rozleg\u0142\u0105 wiedz\u0119 na temat chor\u00f3b rzadkich, w tym dane epidemiologiczne i kliniczne, a tak\u017ce innowacyjne biomarkery. CENTOGENE opracowa\u0142o globaln\u0105, autorsk\u0105 platform\u0119 chor\u00f3b rzadkich opart\u0105 na naszym repozytorium danych z rzeczywistego \u015bwiata, obejmuj\u0105cym oko\u0142o 3 miliardy wa\u017conych punkt\u00f3w danych od ponad 530 000 pacjent\u00f3w z ponad 120 kraj\u00f3w (stan na 31 marca 2020 r.).<\/p>\n<p>Platforma firmy obejmuje dane epidemiologiczne, fenotypowe i genetyczne, kt\u00f3re odzwierciedlaj\u0105 globaln\u0105 populacj\u0119, a tak\u017ce biobank pr\u00f3bek krwi tych pacjent\u00f3w. CENTOGENE uwa\u017ca, \u017ce jest to jedyna platforma, kt\u00f3ra kompleksowo analizuje dane wielopoziomowe w celu lepszego zrozumienia rzadkich chor\u00f3b dziedzicznych, co mo\u017ce pom\u00f3c w identyfikacji pacjent\u00f3w i usprawni\u0107 wprowadzanie lek\u00f3w sierocych na rynek przez naszych partner\u00f3w farmaceutycznych. Na dzie\u0144 31 marca 2020 r. firma wsp\u00f3\u0142pracowa\u0142a z 39 partnerami farmaceutycznymi, obejmuj\u0105cymi ponad 45 r\u00f3\u017cnych chor\u00f3b rzadkich.<\/p>\n<h5>Kontakt:<\/h5>\n<p>CENTOGENE<br \/> Ben Legg<br \/> Komunikacja korporacyjna<br \/> <a href=\"mailto:press@centogene.com\" title=\"Napisz e-mail\">press@centogene.com<\/a><\/p>\n<p>Kontakt dla medi\u00f3w<strong> <\/strong><br \/> Doradztwo FTI<br \/> Bridie Lawlor<br \/> +1.917.929.5684<br \/> <a href=\"mailto:bridie.lawlor@fticonsulting.com\" title=\"Napisz e-mail\">bridie.lawlor@fticonsulting.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 09, 2020 (Globe Newswire) \u2013 Centogene N.V. (Nasdaq: CNTG) (\u201cCentogene\u201d or the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2336","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares | CENTOGENE<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.centogene.com\/pl\/centogene-oglasza-ceny-pierwotnej-i-wtornej-oferty-publicznej-akcji-zwyklych\/\" \/>\n<meta property=\"og:locale\" content=\"pl_PL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares | CENTOGENE\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 09, 2020 (Globe Newswire) \u2013 Centogene N.V. (Nasdaq: CNTG) (\u201cCentogene\u201d or the [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.centogene.com\/pl\/centogene-oglasza-ceny-pierwotnej-i-wtornej-oferty-publicznej-akcji-zwyklych\/\" \/>\n<meta property=\"og:site_name\" content=\"CENTOGENE\" \/>\n<meta property=\"article:published_time\" content=\"2020-07-10T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"740\" \/>\n\t<meta property=\"og:image:height\" content=\"416\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"admincg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Napisane przez\" \/>\n\t<meta name=\"twitter:data1\" content=\"admincg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Szacowany czas czytania\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minuty\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\\\/\"},\"author\":{\"name\":\"admincg\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\"},\"headline\":\"CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares\",\"datePublished\":\"2020-07-10T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\\\/\"},\"wordCount\":677,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\\\/\",\"name\":\"CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares | CENTOGENE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\"},\"datePublished\":\"2020-07-10T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\\\/#breadcrumb\"},\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.centogene.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"name\":\"CENTOGENE\",\"description\":\"Guiding Precision Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.centogene.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pl-PL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\",\"name\":\"CENTOGENE\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pl-PL\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"contentUrl\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"width\":246,\"height\":246,\"caption\":\"CENTOGENE\"},\"image\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/centogene\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UClZxtN_laC1_ZtCdxkasdPQ\",\"https:\\\/\\\/www.instagram.com\\\/_centogene_\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\",\"name\":\"admincg\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/pl\\\/author\\\/admincg\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CENTOGENE og\u0142asza cen\u0119 pierwotnej i wt\u00f3rnej oferty publicznej akcji zwyk\u0142ych | CENTOGENE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.centogene.com\/pl\/centogene-oglasza-ceny-pierwotnej-i-wtornej-oferty-publicznej-akcji-zwyklych\/","og_locale":"pl_PL","og_type":"article","og_title":"CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares | CENTOGENE","og_description":"CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 09, 2020 (Globe Newswire) \u2013 Centogene N.V. (Nasdaq: CNTG) (\u201cCentogene\u201d or the [&hellip;]","og_url":"https:\/\/www.centogene.com\/pl\/centogene-oglasza-ceny-pierwotnej-i-wtornej-oferty-publicznej-akcji-zwyklych\/","og_site_name":"CENTOGENE","article_published_time":"2020-07-10T00:00:00+00:00","og_image":[{"width":740,"height":416,"url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp","type":"image\/webp"}],"author":"admincg","twitter_card":"summary_large_image","twitter_misc":{"Napisane przez":"admincg","Szacowany czas czytania":"3 minuty"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.centogene.com\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/#article","isPartOf":{"@id":"https:\/\/www.centogene.com\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/"},"author":{"name":"admincg","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b"},"headline":"CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares","datePublished":"2020-07-10T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.centogene.com\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/"},"wordCount":677,"commentCount":0,"publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"pl-PL","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.centogene.com\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.centogene.com\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/","url":"https:\/\/www.centogene.com\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/","name":"CENTOGENE og\u0142asza cen\u0119 pierwotnej i wt\u00f3rnej oferty publicznej akcji zwyk\u0142ych | CENTOGENE","isPartOf":{"@id":"https:\/\/www.centogene.com\/#website"},"datePublished":"2020-07-10T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.centogene.com\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/#breadcrumb"},"inLanguage":"pl-PL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.centogene.com\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.centogene.com\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.centogene.com\/"},{"@type":"ListItem","position":2,"name":"CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares"}]},{"@type":"WebSite","@id":"https:\/\/www.centogene.com\/#website","url":"https:\/\/www.centogene.com\/","name":"CENTOGENE","description":"Kierowanie medycyn\u0105 precyzyjn\u0105","publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.centogene.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pl-PL"},{"@type":"Organization","@id":"https:\/\/www.centogene.com\/#organization","name":"CENTOGENE","url":"https:\/\/www.centogene.com\/","logo":{"@type":"ImageObject","inLanguage":"pl-PL","@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","contentUrl":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","width":246,"height":246,"caption":"CENTOGENE"},"image":{"@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/centogene","https:\/\/www.youtube.com\/channel\/UClZxtN_laC1_ZtCdxkasdPQ","https:\/\/www.instagram.com\/_centogene_\/"]},{"@type":"Person","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b","name":"admincg","url":"https:\/\/www.centogene.com\/pl\/author\/admincg\/"}]}},"_links":{"self":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts\/2336","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/comments?post=2336"}],"version-history":[{"count":0,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts\/2336\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/media?parent=2336"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/categories?post=2336"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/tags?post=2336"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}